Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.
Abstract: The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
Type:
Grant
Filed:
October 3, 2013
Date of Patent:
September 2, 2014
Assignee:
Biogen Idec Inc.
Inventors:
Christine A. White, Antonio J. Grillo-Lopez
Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.
Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
Type:
Application
Filed:
October 3, 2013
Publication date:
January 30, 2014
Applicant:
Biogen Idec Inc.
Inventors:
Christine A. White, Antonio J. Grillo-Lopez
Abstract: Provided are methods of separating an immunoreactive compound from at least one immaterial component, using a simulated moving bed (“SMB”) system and a SMB apparatus for use in these methods. Also provided are purified immunoreactive compounds prepared using the SMB methods and apparatus and methods of treatment with the purified immunoreactive compounds.
Type:
Grant
Filed:
May 21, 2007
Date of Patent:
December 17, 2013
Assignee:
Biogen Idec Inc.
Inventors:
Jorg Thommes, Alan M. Sonnenfeld, John P. Pieracci, Lynn Conley, Marc Bisschops, Maarten Pennings
Abstract: Disclosed is a method for enhancing or increasing the concentration of biological product in a final mixture, wherein said biological product has one or more selected characteristics, wherein said method comprises: (a) allowing an initial mixture of biological products with and without said selected characteristics to contact a chromatography medium wherein the quantity of biological products in said initial mixture exceeds the binding capacity or the dynamic binding capacity of said chromatography medium; (b) allowing biological product not having said one or more selected characteristics to be separated by said chromatography medium; and (c) recovering a final mixture of biological products from said chromatography medium wherein said final mixture comprises an enhanced or increased concentration of biological product with one or more selected characteristics, compared to the concentration of biological product in said initial mixture.
Abstract: The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
Abstract: This invention concerns methods for the treatment of intermediate and high-grade non-Hodgkins lymphomas, comprising the administration of anti-CD20 monoclonal antibodies and fragments thereof. Particular embodiments include the administration of chimeric anti-CD20 antibody, either alone or in combination with radiolabeled antibodies or chemotherapy. The invention is particularly useful for lymphomas characterized by a high number of circulating B cells, possibly bone marrow involvement, bulky disease, or the involvement of extralymphatic organs or sites.
Abstract: The present invention provides non-fucosylated therapeutic antibodies. More particularly, the invention provides non-fucosylated anti-CD20, anti-CD23 and anti-CD80 antibodies, which show enhanced antibody effector functions. Also provided are cells expressing the non-fucosylated antibodies and therapeutic methods using the non-fucosylated antibodies.
Type:
Application
Filed:
March 28, 2008
Publication date:
July 18, 2013
Applicant:
BIOGEN IDEC INC.
Inventors:
Mitchell Reff, Kandasamy Hariharan, MacLaren Ann, Sisk William
Abstract: The present invention provides a method for treating multiple sclerosis (MS), and for reducing flu-like symptoms associated with administration of an interferon to a patient with MS. The method involves intramuscularly administering the interferon to the MS patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. In one embodiment of the invention, the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3. Also provided are titration packages for enabling compliance with a regimen of changing dosage of an interferon over a period of time.
Abstract: The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
Abstract: Methods are disclosed of treating rheumatoid arthritis in a human comprising administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab and administering methotrexate to the human.
Type:
Grant
Filed:
May 4, 2000
Date of Patent:
October 26, 2010
Assignees:
Biogen Idec, Inc., Genentech, Inc.
Inventors:
John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
Abstract: Compositions comprising CD80-targeted therapeutics and methods of using these compositions are provided for the treatment of a disease or disorder in which CD80-expressing cells or regulatory T cell function contribute to or exacerbate the associated pathology.
Abstract: Compositions comprising CD80 antagonists and methods using these compositions are provided for the treatment of Hodgkins lymphoma. More particularly, the disclosed CD80 antagonists may be used to induce apoptosis or lysis of Hodgkins Reed-Sternberg (HRS) cells, or to inhibit HRS cell activities that promote tumor development or progression.
Type:
Application
Filed:
March 28, 2008
Publication date:
July 29, 2010
Applicant:
BIOGEN IDEC INC.
Inventors:
Arturo Molina, Kandasamy Hariharan, Steffan Ho